Use of Seroquel XR and Seroquel IR for schizophrenia
This study is completed in Sweden. It is testing Use of Seroquel XR and Seroquel IR for schizophrenia.
SchizophreniaObservationalFrom 18 Years to 65 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
In plain English
Key information made simple
What is this study testing?
This observational study follows adults living with schizophrenia to understand their experience, outcomes, or changes over time.
What would participation involve?
Participants may answer questionnaires, join interviews, or provide follow-up information, attend study visits with the research team. The registry lists locations in Sweden.
Who is it mainly for?
This study appears to be mainly for adults with schizophrenia.
What should you check before joining?
Ask about whether there is a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
Check the study details
Check the official source, then confirm these points with the research team.
The overall study status can differ from each site's status. Open a country to see its locations and their registry status.
Sweden · 14 sites
Research Site
Falköping
Site status: Not listed — confirm with the team
Research Site
Gothenburg
Site status: Not listed — confirm with the team
Research Site
Helsingborg
Site status: Not listed — confirm with the team
Research Site
Karlskrona
Site status: Not listed — confirm with the team
Research Site
Karlstad
Site status: Not listed — confirm with the team
Research Site
Lund
Site status: Not listed — confirm with the team
Research Site
Malmö
Site status: Not listed — confirm with the team
Research Site
Mölndal
Site status: Not listed — confirm with the team
Research Site
Öjebyn
Site status: Not listed — confirm with the team
Research Site
Stockholm
Site status: Not listed — confirm with the team
Research Site
Trollhättan
Site status: Not listed — confirm with the team
Research Site
Umeå
Site status: Not listed — confirm with the team
Research Site
Uppsala
Site status: Not listed — confirm with the team
Research Site
Vaxjo
Site status: Not listed — confirm with the team
Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: NCT01214135. We help you review the study, but cannot decide medical eligibility.
In practice
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Important
Not medical advice
Information from public sources.
Are you the study sponsor? Contact us to update this page: hi@hopestage.com
FAQ
Questions about this study
What is this study trying to understand?
This study is exploring observational follow-up for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Is this an interview, survey, or observational study?
This appears to be a interview / survey / observational study. Phase is mainly useful to check for medication studies and some device studies.
Who might this study be for?
This study may concern people with schizophrenia; age range: From 18 Years to 65 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to answer questionnaires or take part in interviews. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
Could the questions feel emotionally difficult or personal?
If the study involves interviews or questionnaires, some questions may feel personal or emotionally sensitive. Ask whether you can skip questions, pause, stop, and how your answers will be protected. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by AstraZeneca, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Explore other studies
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.